ArticleDrug design, development and therapy2026
Benzodiazepine Use Among Patients Receiving Methadone Maintenance Treatment: A Descriptive Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the patterns and characteristics of benzodiazepine (BZD) use among patients receiving methadone maintenance treatment (MMT). Methods: A total of 80 participants (40 with and 40 without BZD use) were recruited from the MMT clinic of the Affiliated Kangning Hospital of Ningbo University between April 2024 and March 2025. All participants were assessed using the BZD Use Questionnaire (BUQ), the Chinese version of Barratt impulsiveness scale (BIS-C), the Self-rating Anxiety Scale (SAS), the Self-rating Depression Scale (SDS), and the Quality of Life Scale for Drug Addicts (QOL-DA). Results: Among 80 initially selected participants, 71 (BZD group: n=39; non-BZD group: n=32) were included in the final analysis after exclusions for invalid data. In univariate comparisons, the BZD group had a significantly higher prevalence of comorbid mental, sleep, and chronic disorders, higher scores on impulsivity (total, motor, and non-planning), anxiety, and depression scales, and lower scores on the total score as well as the psychological and symptoms/side effects domains of the QOL-DA (all P < 0.05). However, after adjusting for potential confounders, multivariate regression analyses indicated that BZD use was independently associated with higher anxiety levels (β = 0.279, P < 0.05) and greater total impulsivity (β = 0.439, P < 0.001). Regarding impulsivity subscales, BZD use was independently associated with non-planning (β = 0.265, P < 0.05) and motor impulsivity (β = 0.345, P < 0.05), but not with attentional impulsivity. No significant independent associations were found between BZD use and depression or any domain of quality of life (all P > 0.05). Conclusion: BZD use was independently associated with higher levels of impulsivity and anxiety after controlling for key comorbidities, but not with depression or QOL. The causal direction between BZD use and increased impulsivity/anxiety in MMT patients remains unclear, potentially reflecting either pharmacological effects or pre-existing higher levels of impulsivity or anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.